m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT05691
|
[1] | |||
m6A modification
miR-92b-5p
miR-92b-5p
WTAP
Methylation
: m6A sites
Direct
Inhibition
Non-coding RNA
miR-92b-5p
TIMP4
lncRNA miRNA circRNA
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | Wilms tumor 1-associating protein (WTAP) | WRITER | |||
| m6A Target | hsa-miR-92b-5p | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | Non-coding RNA (ncRNA) | ||||
| Epigenetic Regulator | hsa-miR-92b-5p | microRNA | View Details | ||
| Regulated Target | Metalloproteinase inhibitor 4 (TIMP4) | View Details | |||
| Crosstalk Relationship | m6A → ncRNA | Inhibition | |||
| Crosstalk Mechanism | m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA | ||||
| Crosstalk Summary | m6A modification mediated by WTAP promotes the maturation of pri-miR-92b to hsa-miR-92b-5p, thereby enhancing the targeted inhibitory function of miR-92b-5p on Metalloproteinase inhibitor 4 (TIMP4). Furthermore, we have discovered that WTAP can directly facilitate the degradation of TIMP4 mRNAs in a YTHDF2-dependent manner. | ||||
| Responsed Disease | Osteoarthritis | ICD-11: FA05 | |||
| Cell Process | Cell apoptosis | ||||
| Cell proliferation | |||||
| In-vivo Model | The male C57BL/6 mice (SPF, Eight-week-old) were randomly divided into four groups: sham (n = 6), model (n = 6), model + adeno-associated virus-negative control (AVV-shNC) (n = 6), and model + AVV-shWTAP groups (n = 6). After acclimating for one week, mice in other groups were treated with DMM surgery to induce OA as previously described except for the sham groups [19]. The mice in sham group were underwent only the skin of the right knee joint incision. The AAV-shNC and AAV-shWTAP were constructed by HANBIO (Shanghai, China). The AAV-shNC and AAV-shWTAP groups were intra-articularly injected with 10 μL of AAV-shNC and AAV-shWTAP (1 × 1013 vg/ml) through the medial parapatellar area at two weeks after the DMM operation, respectively. | ||||
: m6A sites